Foghorn co-founder re­signs from board; Guardant and Mer­ck KGaA team up again

Cigall Kadoch has won an ap­point­ment as an in­ves­ti­ga­tor at the Howard Hugh­es Med­ical In­sti­tute — and sub­se­quent­ly will be re­sign­ing from Flag­ship’s Foghorn Ther­a­peu­tics board.

Kadoch, who co-found­ed Foghorn in 2016, will con­tin­ue work­ing with the com­pa­ny, but as a sci­en­tif­ic ad­vi­sor. Foghorn CEO Adri­an Gottschalk said in a pre­pared state­ment:

I want to con­grat­u­late Cigall on her ap­point­ment to HH­MI. Cigall’s work on the role of the chro­matin reg­u­la­to­ry sys­tem in dis­ease has been an in­spi­ra­tion for Foghorn. Cigall’s ap­point­ment to HH­MI is a tes­ta­ment to her lead­er­ship in the field. I look for­ward to con­tin­u­ing to work close­ly with Cigall in her new role as we ad­vance our ef­forts to help pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER